Literature DB >> 25347011

Measureable residual disease (MRD): much ado about nothing?

R P Gale1.   

Abstract

Mesh：

Year:  2014        PMID： 25347011     DOI： 10.1038/bmt.2014.239

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

Review 1.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

2.  Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Authors:  Matthew P Mulé; Gabriel N Mannis; Brent L Wood; Jerald P Radich; Jimmy Hwang; Nestor R Ramos; Charalambos Andreadis; Lloyd Damon; Aaron C Logan; Thomas G Martin; Christopher S Hourigan
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-17       Impact factor: 5.742

3.  Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Authors:  Ya-Zhen Qin; Yu Wang; Hong-Hu Zhu; Robert Peter Gale; Mei-Jie Zhang; Qian Jiang; Hao Jiang; Lan-Ping Xu; Huan Chen; Xiao-Hui Zhang; Yan-Rong Liu; Yue-Yun Lai; Bin Jiang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Chin J Cancer       Date:  2016-05-19

4.  New drug approvals in acute myeloid leukemia: what's the best end point?

Authors:  E Estey; M Othus; S J Lee; F R Appelbaum; R P Gale
Journal:  Leukemia       Date:  2015-12-18       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.